News & Events zu Arcus Biosciences Inc (RCUS)

$18.140

+0.388 (+2.14%)Zum Schluss

RCUS-News

5.010-26Newsfilter

Arcus Biosciences Grants Stock Options to New Employees

8.510-22Newsfilter

Arcus Biosciences Prices Public Offering at $17.50 per Share

8.510-21Newsfilter

Arcus Biosciences Launches Underwritten Public Offering

9.510-20CNBC

Hasbro Reports Strong Q3 Results, Raises Revenue Outlook

9.010-20Newsfilter

New Data on Casdatifan for Kidney Cancer Released

6.010-14CNBC

Key Wall Street Rating Changes on Wednesday

5.010-09Newsfilter

Arcus Biosciences Grants Stock Options to New Employees

5.009-24Newsfilter

Arcus Biosciences Grants Stock Options to New Employees

8.509-22Newsfilter

Arcus Biosciences to Host Investor Event Highlighting New Data on Casdatifan

2.009-11NASDAQ.COM

Arcus Biosciences Stock Shows Oversold Signal

Mehr News anzeigen

RCUS-Events

10/22 06:30

Jefferies and Others Jointly Manage Offering with Price Range of $17.50-$18.50

The deal range was $17.50-$18.50. Jefferies, Leerink and TD Cowen acted as joint book running managers for the offering.

10/21 17:00

Jefferies, Leerink, and TD Cowen Jointly Manage New Stock Offering

Jefferies, Leerink and TD Cowen are acting as joint book running managers for the offering.

10/21 16:30

Arcus Biosciences Launches Underwritten Public Offering of Common Stock

Arcus Biosciences announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. Jefferies, Leerink Partners and TD Cowen are acting as joint book-running managers.

10/21 12:30

Arcus Biosciences Shares Down 8.3% to $21.77

Arcus Biosciences is down -8.3%, or -$1.98 to $21.77.

10/18 16:00

Management Discusses New Data for Casdatifan Kidney Cancer Treatment

Management discusses new data for Casdatifan as a treatment for Kidney Cancer across multiple lines of therapy in a virtual meeting to be held on October 20 at 8:30 am.

Mehr Events anzeigen

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.